Clinical Trials Logo

Clinical Trial Summary

Observational, multi-centre, prospective study to investigate the feasibility of centralized TDM of moxifloxacin and levofloxacin in MDR-TB patients by determining turn-around time between sampling and receiving dosing advice.

In addition, the effect of TDM will be evaluated by comparing treatment results of prospective patients receiving TDM with historical controls without TDM.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03409315
Study type Observational
Source University Medical Center Groningen
Contact Jan-WIllem Alffenaar, PhD
Phone +31503614071
Status Recruiting
Start date February 10, 2018
Completion date December 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Recruiting NCT03086486 - Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) Phase 3
Completed NCT01201941 - Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru N/A
Recruiting NCT03303963 - DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Recruiting NCT02413931 - Nosocomial Transmission of MDR-TB in Bucharest, Romania
Recruiting NCT02597621 - Biomarkers for Therapy Response in Drug-resistant Tuberculosis N/A
Completed NCT02573350 - A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Phase 2
Recruiting NCT03237182 - The Individualized M(X) Drug-resistant TB Treatment Strategy Study Phase 4
Recruiting NCT03338621 - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Phase 2/Phase 3
Not yet recruiting NCT03828201 - Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB Phase 3
Recruiting NCT02589782 - Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Phase 2/Phase 3
Recruiting NCT02619994 - Treatment Shortening of MDR-TB Using Existing and New Drugs Phase 2
Active, not recruiting NCT01918397 - Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Phase 2
Completed NCT00513396 - High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Phase 2/Phase 3
Recruiting NCT03259269 - Expand New Drugs for TB [endTB]
Completed NCT01071603 - Tuberculosis in China
Completed NCT02365623 - An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) Phase 2
Recruiting NCT02754765 - Evaluating Newly Approved Drugs for Multidrug-resistant TB Phase 3
Not yet recruiting NCT03728725 - Xpert MTB/XDR Clinical Evaluation Trial
Completed NCT02170441 - Global Consortium for Drug-resistant Tuberculosis Diagnostics N/A